Develop and manufacture biotherapeutics that address significant medical needs.
Participated in several meetings and discussions on evolving principles/specifications for health care reform bills being developed by congressional committees.  Discussions included the following subjects: government reimbursement for biotherapeutics, comparative effectiveness research, and legislative and regulatory issues involved in FDA approval of follow-on biologics. Public Law 111-5, the American Recovery and Reinvestment Act of 2009 - government reimbursement for biotherapeutics
S. Con. Res. 13, Concurrent Resolution on the Budget, FY 2010 - government reimbursement for biotherapeutics.
H. Con. Res. 85, Concurrent Resolution on the Budget, FY 2010 - government reimbursement for biotherapeutics. H.R. 1548, the Pathway for Biosimilars Act, FDA approval of follow-on biologics.
H.R. 1427 and S. 726, the Promoting Innovation and Access to Life-Saving Medicine Act, FDA approval of follow-on biologics.
S. Con. Res. 13, Concurrent Resolution on the Budget, FY 2010 - FDA approval of follow-on biologics.
H. Con. Res. 85, Concurrent Resolution on the Budget, FY 2010 - FDA approval of follow-on biologics. Public Law 111-5, the American Recovery and Reinvestment Act of 2009 - funding for comparative effectiveness research.
Draft legislation - the Comparative Effectiveness Research Act - authorization for comparative effectiveness research.
S. Con. Res. 13, Concurrent Resolution on the Budget, FY 2010 - government uses of comparative effectiveness research.
H. Con. Res. 85, Concurrent Resolution on the Budget, FY 2010 - government uses of comparative effectiveness research.
HCR - Health Issues MMM - Medicare/Medicaid PHA - Pharmacy MED - Medical/Disease Research/Clinical Labs
11 - Executive Office of the President (EOP) 2 - HOUSE OF REPRESENTATIVES 18 - Office of Management & Budget (OMB) 1 - SENATE 11 - Executive Office of the President (EOP) 2 - HOUSE OF REPRESENTATIVES 18 - Office of Management & Budget (OMB) 1 - SENATE 11 - Executive Office of the President (EOP) 2 - HOUSE OF REPRESENTATIVES 18 - Office of Management & Budget (OMB) 1 - SENATE 11 - Executive Office of the President (EOP) 2 - HOUSE OF REPRESENTATIVES 18 - Office of Management & Budget (OMB) 1 - SENATE
TARPLIN STRATEGIES LLC
975 F Street NW Suite 500, Washington, DC, 20004, US
RICHARD JOSEPH TARPLIN (and Families) RICHARD JOSEPH TARPLIN (and Families) RICHARD JOSEPH TARPLIN (and Families) RICHARD JOSEPH TARPLIN (and Families)
and Families and Families and Families and Families